1
|
Radin M, Arbrile M, Cecchi I, Barinotti A, Baldovino S, Menegatti E, Rossi D, Sciascia S, Roccatello D. POS0507 TAILORING ORAL THERAPY IN RHEUMATOID ARTHRITIS: THE TuTOR APP. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.757] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundMedication non-adherence has a significant impact on the health and well-being of individuals with chronic diseases. Indeed, with respect to important risk factors of Rheumatoid Arthritis (RA), such as cardiovascular risk factors, it is known that up to 50% of patients will stop taking medication for these conditions during the first year of prescription [1].ObjectivesTo support the management of RA patients treated with Tofacitinib, we designed the TuTOR (Tailoring Tofacitinib Oral therapy in Rheumatoid arthritis) Mobile App.MethodsA prospective-controlled study evaluated the impact of TuTOR App on medical adherence in 20 RA patients, that began treatment with Tofacitinib jointly with the App. We used a crossover design alternating Paper-Diary and TuTOR App, with monthly clinical assessments.ResultsSeventeen patients with RA (mean age at inclusion 59±13yrs; 88% females) the study. A statistically significant decrease of DAS28 was observed since the first month of therapy with Tofacitinib (mean DAS28 at baseline 3.9±1 vs. 1° month 3.1±1, p=0.0016). Similarly, Numerical Rating Scale(NRS) of perceived activity of disease (5.8±2.1 vs.3.7±2.5, p=0.02), and subjective fatigue (6.1±2.3 vs 4.3±2.6; p=0.01) progressively decreased. No differences were reported in DAS28 and in all the NRS between the use of the TuTOR App and the Paper-Diary. A significant decrease was observed also in HAQ during the follow-up (baseline 1.38±1.11 vs.six months 0.83±0.9; p=0.01).Most of the patients (82%) when filling out the self-reporting questionnaires preferred the TuTOR App in helping them to remember to take the pills. Further 82% of patients used the TuTOR App regularly (vs.53% Paper-Diary) and 76% of patients would use it in the future (vs.53% Paper-Diary). Three patients suspended the therapy with Tofacitinib due to gastrointestinal intolerance.ConclusionBoth digital- and paper-devices can help maximize the adherence to therapy, leading to an improvement in disease’s activity, highlighting the need of supports for medication adherence.References[1]BJ van den B, HE Z, CH van den E. Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature. Expert Rev Clin Immunol 2012;8:337–351. Available at: https://pubmed.ncbi.nlm.nih.gov/22607180/. Accessed July 13, 2021.Table 1.Baseline demographic and clinical characteristics of the patients enrolled in the study, who completed follow-up. RA – Rheumatoid ArthritisPatients with RA(N=17)DEMOGRAPHICSAge (mean ± S.D.)59,4 ± 13,5Sex (n; %)M (2; 11,8), F (15; 88,2)Etnicity (caucasian; n; %)16; 94Etnicity (Hispanic; n; %)1; 6CLINICAL CHARACTERISTICSAge at diagnosis (mean ± S.D.)44,7±14,47Follow-up length (years; mean ± S.D.)6,33± 5,17Positive Rheumatoid Factor (n; %)17; 100Positive Anti-Cyclic citrullinated peptides (n;%)15; 88.2Structural articular damage at radiography (n; %)11; 7Figure 1.Decrease of disease activity assessed by DAS28 in the paper-diary and TuTOR App groups.Disclosure of InterestsMassimo Radin Grant/research support from: The study is supported by the Investigator-Initiated Research Studies Grant—CREARE (Pfizer)., Marta Arbrile: None declared, Irene Cecchi Grant/research support from: The study is supported by the Investigator-Initiated Research Studies Grant—CREARE (Pfizer)., Alice Barinotti: None declared, Simone Baldovino: None declared, Elisa Menegatti: None declared, Daniela Rossi Grant/research support from: The study is supported by the Investigator-Initiated Research Studies Grant—CREARE (Pfizer)., Savino Sciascia Grant/research support from: The study is supported by the Investigator-Initiated Research Studies Grant—CREARE (Pfizer)., Dario Roccatello Grant/research support from: The study is supported by the Investigator-Initiated Research Studies Grant—CREARE (Pfizer).
Collapse
|
2
|
Affiliation(s)
- S Sciascia
- Center for Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, and SCDU Nephrology and Dialysis, S. Giovanni Bosco Hospital, Turin, Italy
| | - M Radin
- Center for Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, and SCDU Nephrology and Dialysis, S. Giovanni Bosco Hospital, Turin, Italy.,School of Specialization of Clinical Pathology, Department of Clinical and Biological Sciences, University of Turin, Italy
| | - S Baldovino
- Center for Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, and SCDU Nephrology and Dialysis, S. Giovanni Bosco Hospital, Turin, Italy.,School of Specialization of Clinical Pathology, Department of Clinical and Biological Sciences, University of Turin, Italy
| | - D Roccatello
- Center for Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, and SCDU Nephrology and Dialysis, S. Giovanni Bosco Hospital, Turin, Italy
| |
Collapse
|
3
|
Roccatello D, Sciascia S, Rossi D, Naretto C, Bazzan M, Solfietti L, Sandrone M, Radin M, Baldovino S, Menegatti E. Safety of outpatient percutaneous native renal biopsy in systemic autoimmune diseases: results from a monocentric cohort. Lupus 2018; 27:1393-1394. [PMID: 29325491 DOI: 10.1177/0961203317751645] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- D Roccatello
- 1 Center of Research of Immunopathology and Rare Diseases-Coordinating Center of the Network for Rare Diseases of Piedmont and Aosta Valley, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.,2 Nephrology and Dialysis Unit, S. Giovanni Bosco Hospital and University of Turin, Turin, Italy
| | - S Sciascia
- 1 Center of Research of Immunopathology and Rare Diseases-Coordinating Center of the Network for Rare Diseases of Piedmont and Aosta Valley, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.,2 Nephrology and Dialysis Unit, S. Giovanni Bosco Hospital and University of Turin, Turin, Italy
| | - D Rossi
- 1 Center of Research of Immunopathology and Rare Diseases-Coordinating Center of the Network for Rare Diseases of Piedmont and Aosta Valley, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
| | - C Naretto
- 1 Center of Research of Immunopathology and Rare Diseases-Coordinating Center of the Network for Rare Diseases of Piedmont and Aosta Valley, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
| | - M Bazzan
- 3 UOSD Hematology and Thrombosis Unit, S. Giovanni Bosco Hospital, Turin, Italy
| | - L Solfietti
- 1 Center of Research of Immunopathology and Rare Diseases-Coordinating Center of the Network for Rare Diseases of Piedmont and Aosta Valley, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
| | - M Sandrone
- 4 Radiology Department, S. Giovanni Bosco Hospital, Turin, Italy
| | - M Radin
- 1 Center of Research of Immunopathology and Rare Diseases-Coordinating Center of the Network for Rare Diseases of Piedmont and Aosta Valley, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
| | - S Baldovino
- 1 Center of Research of Immunopathology and Rare Diseases-Coordinating Center of the Network for Rare Diseases of Piedmont and Aosta Valley, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
| | - E Menegatti
- 1 Center of Research of Immunopathology and Rare Diseases-Coordinating Center of the Network for Rare Diseases of Piedmont and Aosta Valley, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
| |
Collapse
|
4
|
Radin M, Schreiber K, Costanzo P, Cecchi I, Roccatello D, Baldovino S, Bazzan M, Cuadrado MJ, Sciascia S. The adjusted Global AntiphosPholipid Syndrome Score (aGAPSS) for risk stratification in young APS patients with acute myocardial infarction. Int J Cardiol 2017; 240:72-77. [PMID: 28385357 DOI: 10.1016/j.ijcard.2017.02.155] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/15/2017] [Revised: 02/21/2017] [Accepted: 02/28/2017] [Indexed: 01/21/2023]
Abstract
BACKGROUND Young adults with acute myocardial infarction are a critical group to examine for the purpose of risk factor stratification and modification. In this study we aimed to assess the clinical utility of the adjusted Global AntiphosPholipid Syndrome Score (aGAPSS) for the risk stratification of acute myocardial infarction in a cohort of young patients with antiphospholipid syndrome (APS). METHODS The analysis included 83 consecutive APS patients (≤50years old) who presented with arterial or venous thromboembolic events. Data on cardiovascular risk factors and antiphospholipid antibodies (aPL) positivity were retrospectively collected. The aGAPSS was calculated by adding the points corresponding to the risk factors, based on a linear transformation derived from the ß-regression coefficient as follows: 3 for hyperlipidaemia, 1 for arterial hypertension, 5 for aCL IgG/IgM, 4 for anti-b2 glycoprotein I IgG/IgM and 4 for LA. RESULTS Higher aGAPSS values were observed in patients with acute myocardial infarction when compared to the others [mean aGAPSS 11.9 (S.D. 4.15, range 4-18) Vs. mean aGAPSS 9.2 (S.D. 5.1, range 1-17); T test: p<0.05]. Significantly higher aGAPSS values were also seen in patients with acute coronary syndrome compared to patients with a history of peripheral or cerebrovascular arterial thrombotic events [mean aGAPSS 11.9 (S.D. 4.15, range 4-18) Vs. mean aGAPSS 6.7 (S.D. 5.7, range 1-17); T test: P<0.005]. CONCLUSIONS The aGAPSS is based upon a quantitative score and could aid risk stratifying APS patients younger than 50years for the likelihood of developing coronary thrombotic events and may guide pharmacological treatment for high-risk patients.
Collapse
Affiliation(s)
- M Radin
- Center of Research of Immunopathology and Rare Diseases-Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, and SCDU Nephrology and Dialysis, S. Giovanni Bosco Hospital and University of Turin, Turin, Italy
| | - K Schreiber
- Department of Thrombosis and Haemophilia, Guy's and St Thomas' Hospital, London, United Kingdom; Department of Rheumatology, Copenhagen University Hospital, Copenhagen, Denmark
| | - P Costanzo
- Cardiology Departiment, S. Giovanni Bosco Hospital, Turin, Italy
| | - I Cecchi
- Center of Research of Immunopathology and Rare Diseases-Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, and SCDU Nephrology and Dialysis, S. Giovanni Bosco Hospital and University of Turin, Turin, Italy
| | - D Roccatello
- Center of Research of Immunopathology and Rare Diseases-Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, and SCDU Nephrology and Dialysis, S. Giovanni Bosco Hospital and University of Turin, Turin, Italy
| | - S Baldovino
- Center of Research of Immunopathology and Rare Diseases-Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, and SCDU Nephrology and Dialysis, S. Giovanni Bosco Hospital and University of Turin, Turin, Italy
| | - M Bazzan
- UOSD Hematology and Thrombosis Unit, S. Giovanni Bosco Hospital, Turin, Italy
| | - M J Cuadrado
- Louise Coote Lupus Unit, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - S Sciascia
- Center of Research of Immunopathology and Rare Diseases-Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, and SCDU Nephrology and Dialysis, S. Giovanni Bosco Hospital and University of Turin, Turin, Italy.
| |
Collapse
|
5
|
Sciascia S, Baldovino S, Roccatello D, Cuadrado M. THU0308 Hydroxychloroquine Improves Pregnancy Outcome in Women with Antiphospholipid Antibodies without Other Underlying Connective Tissue Disease. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.6118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
6
|
Sciascia S, Baldovino S, Menegatti E, Solfietti L, Di Simone D, Rossi D, Roccatello D. FRI0347 Phenotypic Changes of Lymphocytes in Patients with Severe Systemic Lupus Erythematosus Treated with An Intensified B-Cell Depletion Therapy with Rituximab. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.4609] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
7
|
Quartuccio L, Zuliani F, Corazza L, Scaini P, Zani R, Lenzi M, Tavoni A, Sebastiani M, Baldovino S, Urraro T, Saccardo F, Sbreglia C, Mazzaro C, Pioltelli P, Fraticelli P, Filippini D, Gabrielli A, Perrella O, Scarpato S, Roccatello D, Zignego A, Ferri C, Bombardieri S, Pietrogrande M, Galli M, Monti G, De Vita S. OP0228 Rituximab Monotherapy of Severe Hcv-Related Cryoglobulinemic Vasculitis for More than 2 Years: Follow-Up of A Randomized Controlled Multicentre Study. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.3872] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
8
|
Monova D, Monov S, Todorov T, Soderberg D, Kurz T, Weiner M, Eriksson P, Segelmark M, Jakuszko K, Sebastian A, Bednarz Z, Krajewska M, Wiland P, Madziarska K, Weyde W, Klinger M, Naidoo J, Wearne N, Jones E, Swanepoel C, Rayner B, Okpechi I, Endo N, Tsuboi N, Furuhashi K, Matsuo S, Maruyama S, Clerte M, Levi C, Touzot M, Fakhouri F, Monge C, Lebas C, Abboud I, Huart A, Durieux P, Charlin E, Thervet E, Karras A, Smykal-Jankowiak K, Niemir ZI, Polcyn-Adamczak M, Whatmough S, Sweeney N, Fernandez S, Hussain M, Dhaygude A, Jakuszko K, Bednarz Z, Sebastian A, Krajewska M, Gniewek K, Wiland P, Weyde W, Klinger M, Manenti L, Urban ML, Vaglio A, Gintoli E, Galletti M, Buzio C, Monova D, Monov S, Argirova T, Wong I, Ibrahim FH, Goh BL, Lim TS, Chan MW, Hiramtasu R, Ubara Y, Hoshino J, Takaichi K, Ghafoor V, Hussain M, Dhaygude A, Whatmough S, Fernandez S, Sweeney N, Hussain M, Dhaygude A, Sahay M, Soma J, Nakaya I, Sasaki N, Yoshikawa K, Sato H, Kaminskyy V, ZAbi Ska M, Krajewska M, Ko Cielska-Kasprzak K, Jakuszko K, Klinger M, Niemir Z, Wozniczka K, Swierzko A, Cedzynski M, Polcyn-Adamczak M, Sokolowska A, Szala A, Arjunan A, Mikhail A, Shrivastava R, Parker C, Aithal S, Gursu M, Ozari M, Yucetas E, Sumnu A, Doner B, Cebeci E, Ozkan O, Aktuglu MB, Karaali Z, Koldas M, Ozturk S, Marco H, Picazo M, Da Silva I, Gonzalez A, Arce Y, Gracia S, Corica M, Llobet J, Diaz M, Ballarin J, Schonermarck U, Hagele H, Baumgartner A, Fischereder M, Muller S, Oliveira CBL, Oliveira ASA, Carvalho CJB, Pessoa CTBC, Sette LHBC, Fernandes GV, Cavalcante MAGM, Valente LM, Wan Q, Hu H, He Y, Li T, Aazair N, Houmaid Z, Rhair A, Bennani N, Demin A, Petrova O, Kotova O, Demina L, Roccatello D, Sciascia S, Rossi D, Naretto C, Baldovino S, Alpa M, Salussola I, Modena V, Zakharova EV, Vinogradova OV, Stolyarevich ES, Yap DYH, Chan TM, Thanaraj V, Dhaygude A, Ponnusamy A, Pillai S, Argentiero L, Schena A, Rossini M, Manno C, Castellano G, Martino M, Mitrotti A, Giliberti M, Digiorgio C, Di Palma AM, Battaglia M, Ditonno P, Grandaliano G, Gesualdo L, Oliveira CBL, Carvalho CJB, Oliveira ASA, Pessoa CTBC, Sette LHBC, Fernandes GV, Cavalcante MAGM, Valente LM, Neprintseva N, Tchebotareva N, Bobkova I, Kozlovskaya L, Rabrenovi V, Kova Evi Z, Jovanovi D, Rabrenovi M, Anti S, Ignjatovi L, Petrovi M, Longhi S, Del Vecchio L, Vigano S, Casartelli D, Bigi MC, Corti M, Limardo M, Tentori F, Pontoriero G, Zeraati AA, Shariati Sarabi Z, Davoudabadi Farahani A, Mirfeizi Z, Bae E. PRIMARY AND SECONDARY GLOMERULONEPHRITIDES 2. Nephrol Dial Transplant 2014. [DOI: 10.1093/ndt/gfu170] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
9
|
Baldovino S, Naretto C, Mereuta M, Sciascia S, Manna E, Salussolia I, Strani G, Giancaspero K, Menegatti E, Roccatello D. C1 esterase inhibitor deficiency and SLE: A case report and review of the literature. Mol Immunol 2013. [DOI: 10.1016/j.molimm.2013.05.122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
10
|
Roccatello D, Sciascia S, Baldovino S, Rossi D. OP0212 Very Long-Term Effects of the “4 Plus 2 Infusion Protocol” of Rituximab Alone in Patients with HCV-Associated Mixed Cryoglobulinemia with Diffuse Membranoproliferative Glomerulonephritis, Severe Polyneuropathy and Necrotic Ulcers of Skin. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.417] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
11
|
Paleari S, Baldovino S, Molle A, Fanciulli M. Evidence of trigonal dangling bonds at the Ge(111)/oxide interface by electrically detected magnetic resonance. Phys Rev Lett 2013; 110:206101. [PMID: 25167431 DOI: 10.1103/physrevlett.110.206101] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/21/2013] [Revised: 03/28/2013] [Indexed: 06/03/2023]
Abstract
Despite a renewed interest in Ge as a competitor with Si for a broad range of electronic applications, the microstructure and the electronic properties of the dangling bonds that, in analogy with Si, are expected at the Ge/oxide interface have escaped a firm spectroscopy observation and characterization. Clear evidence based on contactless electrically detected magnetic resonance spectroscopy of a dangling bond at the Ge(111)/GeO(2) interface is reported in this Letter. This result supports the similarity between dangling bonds at the Si(111)/oxide and Ge(111)/oxide interfaces, both showing C(3v) trigonal point symmetry with the main axis oriented along the ⟨111⟩ direction. In contrast, at the Ge(001)/oxide interface the absence of the trigonal center in favor of a lower symmetry dangling bond marks the difference with the Si(001)/oxide interface, where both centers are present and the one having higher point symmetry prevails. This fact is rationalized in terms of suboxide interface rearrangement and oxide viscoelasticity, which promote the generation of the nonaxial centers at distorted dimers. The unambiguous identification of the centers at the Ge/oxide interfaces yields a deeper insight into the physical properties of the suboxide interface structure and offers a valid indicator for the evaluation of different surface capping and passivation techniques, with the potential to boost the Ge-related technology.
Collapse
Affiliation(s)
- S Paleari
- Dipartimento di Scienza dei Materiali, Università degli Studi di Milano Bicocca, via Cozzi 53, I-20125 Milan, Italy
| | - S Baldovino
- Laboratorio MDM, IMM-CNR, Via C. Olivetti 2, I-20864 Agrate Brianza (MB), Italy
| | - A Molle
- Laboratorio MDM, IMM-CNR, Via C. Olivetti 2, I-20864 Agrate Brianza (MB), Italy
| | - M Fanciulli
- Dipartimento di Scienza dei Materiali, Università degli Studi di Milano Bicocca, via Cozzi 53, I-20125 Milan, Italy and Laboratorio MDM, IMM-CNR, Via C. Olivetti 2, I-20864 Agrate Brianza (MB), Italy
| |
Collapse
|
12
|
Bertero MT, Bazzan M, Carignola R, Montaruli B, Silvestro E, Sciascia S, Vaccarino A, Baldovino S, Roccatello D. Antiphospholipid syndrome in northwest Italy (APS Piedmont Cohort): demographic features, risk factors, clinical and laboratory profile. Lupus 2012; 21:806-9. [PMID: 22635240 DOI: 10.1177/0961203312446974] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
We report the experience from the Antiphospholipid Antibodies (aPL) Regional Consortium in northwest Italy, meant to support clinical research and foster collaboration among health professionals regarding the diagnosis and management of antiphospholipid syndrome (APS) patients. This cohort-study (APS Piedmont Cohort) was designed to register the clinical characteristics at inception and associated immunological manifestations at diagnosis (if any) of patients who strictly fulfilled the current criteria for APS, all recruited at the Piedmont and Valle d'Aosta regions. Clinical and laboratory data from 217 APS patients (171 with vascular events, 33 with pregnancy morbidity and 13 with both), from 16 centres within the geographical area were collected. Venous thrombosis was recorded in 45.6% of patients, arterial thrombosis in 35%, small-vessel thrombosis in 1.12% and mixed arterial and venous thrombosis in the remaining 19.4% of the cases. Pregnancy morbidity included 19 patients with unexplained fetal death beyond the 10th week of pregnancy, 17 with premature birth before the 34th week and 10 with three or more unexplained spontaneous abortions before the 10th week of gestation. This consortium represents an instrument by which to audit clinical practice, to provide counselling to local centres and to sustain future basic and clinical APS research.
Collapse
Affiliation(s)
- M T Bertero
- Immunologia Clinica, AO Ordine Mauriziano, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Roccatello D, Sciascia S, Rossi D, Alpa M, Naretto C, Baldovino S, Menegatti E, La Grotta R, Modena V. Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy. Nephrol Dial Transplant 2011; 26:3987-3992. [DOI: 10.1093/ndt/gfr109] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/30/2023] Open
|
14
|
Sciascia S, Bazzan M, Baldovino S, Vaccarino A, Rossi D, Russo A, Roccatello D. Antiphospholipid syndrome and relapsing polychondritis: an unusual association. Lupus 2011; 20:1336-7. [PMID: 21784779 DOI: 10.1177/0961203311409270] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
15
|
Naretto C, Baldovino S, Rossi E, Spriano M, Roccatello D. The case of SLE associated Sneddon-Wilkinson pustular disease successfully and safely treated with infliximab. Lupus 2009; 18:856-7. [PMID: 19578113 DOI: 10.1177/0961203309103053] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
16
|
Alpa M, Ferrero B, Cavallo R, Naretto C, Menegatti E, Di Simone D, Napoli F, La Grotta R, Rossi D, Baldovino S, Sena L, Roccatello D. Anti-neuronal antibodies in patients with HCV-related mixed cryoglobulinemia. Autoimmun Rev 2008; 8:56-8. [DOI: 10.1016/j.autrev.2008.07.027] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
17
|
Roccatello D, Baldovino S, Alpa M, Rossi D, Napoli F, Naretto C, Cavallo R, Giachino O. Effects of anti-CD20 monoclonal antibody as a rescue treatment for ANCA-associated idiopathic systemic vasculitis with or without overt renal involvement. Clin Exp Rheumatol 2008; 26:S67-S71. [PMID: 18799057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
BACKGROUND Cyclophosphamide (CYC) is thought to be the most effective treatment for antineutrophil cytoplasmatic antibody (ANCA)-associated idiopathic systemic vasculitis with severe organ or life threatening presentation. The key mechanism of action of CYC is suppression of the B lymphocyte activity. However, a considerable minority of patients either remains refractory to conventional therapy or experiences dose-limiting side effects. METHODS In the present study, rituximab (4 weekly doses of 375 mg/m2 and 2 more doses at 1-month interval) was intravenously administered as a rescue therapy to 7 patients (4 affected by idiopathic systemic microscopic polyangiitis, 2 by Wegener's granulomatosis, and 1 affected by Churg Strauss syndrome). The study group was made up of 3 women and 4 men, mean age 61.5 years (39-71), intolerant or refractory to more conventional therapy. Four patients had histologically confirmed paucimmune necrotizing glomerulonephritis. RESULTS Significant decreases were observed in levels of serum creatinine, proteinuria, erythrocyte sedimentation rate, C-reactive protein, and ANCA titers within the first 12 months of follow-up. Arthralgia and weakness rapidly disappeared in all patients. Four out of five patients reported a decrease in the degree of paresthesia, paralleled by an improvement in the electrodiagnostic parameters. A significant improvement was observed in both Birmingham Vasculitis Activity Score and Vasculitis Damage Index. Side effects were negligible. CONCLUSION In this sample of patients with idiopathic systemic vasculitis that was refractory or intolerant to conventional treatment, rituximab was found to be a safe and effective rescue therapy.
Collapse
Affiliation(s)
- D Roccatello
- Centro di Ricerche di Immunopatologia e Documentazione su Malattie Rare, Struttura Complessa a Direzione Universitaria di Immunologia Clinica, Ospedale S.G. Bosco, Torino, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
18
|
Salzano S, Arduino P, Zambruno G, Di Zenzo G, Baldovino S, Roccatello D, Conrotto D, Carrozzo M. OC9 Successful use of mycophenolate mofetil in combination with minocycline in a woman with severe predominantly oral mucous membrane pemphigoid: a case report. Oral Dis 2006. [DOI: 10.1111/j.1601-0825.2006.01308_9.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|